References
Fisher M, Grotta J. Drugs 46: 961–975, 1993
Loscher W, Schmidt D. Epilepsy Res 17: 95–134, 1994
van Zwieten PA. Am Heart J 125: 566–567, 1993
Borcherding SM, et al. Ann Pharmacother 27: 61–67, 1993
Lichtlen PR, et al. Lancet 335: 1109–1113, 1990
Waters D, et al. Circulation 82: 1940–1953, 1990
ter Wee PM, Donker AJM. Kidney Intern 45: 417–424, 1994
Wadworth AN, McTavish D. Drugs Aging 2: 262–286, 1992
Haley EC, et al. Neurology 41 (Suppl. 1): 346, 1991
Ludin HP. Headache 29: 218–223, 1989
Sokya D, et al. Headache 29: 21–27, 1989
Dalessio DJ. Headache Quarterly 4 (Suppl. 2): 12–20, 1993
Mathew NT. Neurology 42 (Suppl. 2): 22–31, 1992
Speckman EJ. Neuropsychobiology 27: 122–126, 1993
Dubovsky SL. Neuwpsychobiology 21: 184–192, 1993
Garza-Trevino ES, et al. Am J Psychiatry 149: 121–122, 1992
Leyland-Jones B, et al. Cancer 72: 3484–3488, 1993
Miller TP, et al. JClin Oncol 9: 17–24, 1991
Rights and permissions
About this article
Cite this article
Broadening horizons for calcium channel blockers. Drugs Ther. Perspect 3, 8–10 (1994). https://doi.org/10.2165/00042310-199403110-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199403110-00004